Company intelligence / Profile preview
Chongqing Peg-Bio Biopharm Co., Ltd.
Beibei District/Liangjiang New Area, Chongqing Shi, Chinapegbiocq.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Other
01
Overview
Developing long-acting biologics with one NDA submission (PB-119 for T2DM) and multiple clinical-stage candidates including oncology programs. Partnering with Huadong Medicine on biosimilars.
- Therapeutic areas
- GastroenterologyEndocrinologyOncologyHematology
- Modalities
- Recombinant proteinsPeptidesBiosimilars
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Huadong Medicine(Semaglutide biosimilar development)[8][9]四环医药/Jilin Sihuan Pharma("Insulin Project")[10]
Beyond the preview
Go deeper on Chongqing Peg-Bio Biopharm Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chongqing Peg-Bio Biopharm Co., Ltd..